Predictive Oncology (POAI) Competitors $5.13 +0.37 (+7.77%) As of 05/20/2026 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock POAI vs. QTI, SKIN, PYPD, STSS, and MDAIShould you buy Predictive Oncology stock or one of its competitors? MarketBeat compares Predictive Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Predictive Oncology include QT Imaging (QTI), Beauty Health (SKIN), PolyPid (PYPD), Sharps Technology (STSS), and Spectral AI (MDAI). These companies are all part of the "medical equipment" industry. POAI vs. QTIPOAI vs. SKINPOAI vs. PYPDPOAI vs. STSSPOAI vs. MDAIHow does Predictive Oncology compare to QT Imaging?Predictive Oncology (NASDAQ:POAI) and QT Imaging (NASDAQ:QTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation. Which has more risk and volatility, POAI or QTI? Predictive Oncology has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, QT Imaging has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Do institutionals and insiders hold more shares of POAI or QTI? 9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 24.2% of QT Imaging shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Comparatively, 28.8% of QT Imaging shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend POAI or QTI? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00QT Imaging 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to POAI or QTI? In the previous week, QT Imaging had 2 more articles in the media than Predictive Oncology. MarketBeat recorded 3 mentions for QT Imaging and 1 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 0.75 beat QT Imaging's score of 0.28 indicating that Predictive Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Predictive Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive QT Imaging 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is POAI or QTI more profitable? QT Imaging has a net margin of -58.93% compared to Predictive Oncology's net margin of -5,065.23%. Predictive Oncology's return on equity of -732.73% beat QT Imaging's return on equity.Company Net Margins Return on Equity Return on Assets Predictive Oncology-5,065.23% -732.73% -235.55% QT Imaging -58.93%-4,220.38%-51.77% Which has stronger valuation & earnings, POAI or QTI? Predictive Oncology has higher earnings, but lower revenue than QT Imaging. QT Imaging is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPredictive Oncology$1.66M10.46-$12.66M-$13.50N/AQT Imaging$18.92M3.21-$21.08M-$1.24N/A SummaryQT Imaging beats Predictive Oncology on 9 of the 15 factors compared between the two stocks.How does Predictive Oncology compare to Beauty Health?Predictive Oncology (NASDAQ:POAI) and Beauty Health (NASDAQ:SKIN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership. Is POAI or SKIN more profitable? Beauty Health has a net margin of -2.03% compared to Predictive Oncology's net margin of -5,065.23%. Beauty Health's return on equity of -9.38% beat Predictive Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Predictive Oncology-5,065.23% -732.73% -235.55% Beauty Health -2.03%-9.38%-1.21% Which has more risk & volatility, POAI or SKIN? Predictive Oncology has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Beauty Health has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Does the media refer more to POAI or SKIN? In the previous week, Beauty Health had 11 more articles in the media than Predictive Oncology. MarketBeat recorded 12 mentions for Beauty Health and 1 mentions for Predictive Oncology. Beauty Health's average media sentiment score of 0.84 beat Predictive Oncology's score of 0.75 indicating that Beauty Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Predictive Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beauty Health 6 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, POAI or SKIN? Beauty Health has higher revenue and earnings than Predictive Oncology. Beauty Health is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPredictive Oncology$1.66M10.46-$12.66M-$13.50N/ABeauty Health$300.80M0.28-$9.52M-$0.17N/A Do analysts prefer POAI or SKIN? Beauty Health has a consensus price target of $2.02, suggesting a potential upside of 206.11%. Given Beauty Health's stronger consensus rating and higher possible upside, analysts plainly believe Beauty Health is more favorable than Predictive Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Beauty Health 1 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals hold more shares of POAI or SKIN? 9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 93.3% of Beauty Health shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by insiders. Comparatively, 40.3% of Beauty Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryBeauty Health beats Predictive Oncology on 13 of the 16 factors compared between the two stocks.How does Predictive Oncology compare to PolyPid?Predictive Oncology (NASDAQ:POAI) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings. Does the media favor POAI or PYPD? In the previous week, PolyPid had 10 more articles in the media than Predictive Oncology. MarketBeat recorded 11 mentions for PolyPid and 1 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 0.75 beat PolyPid's score of -0.08 indicating that Predictive Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Predictive Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PolyPid 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of POAI or PYPD? 9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by company insiders. Comparatively, 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable valuation and earnings, POAI or PYPD? Predictive Oncology has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPredictive Oncology$1.66M10.46-$12.66M-$13.50N/APolyPidN/AN/A-$34.17M-$1.91N/A Is POAI or PYPD more profitable? PolyPid has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. PolyPid's return on equity of -241.96% beat Predictive Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Predictive Oncology-5,065.23% -732.73% -235.55% PolyPid N/A -241.96%-126.91% Which has more volatility & risk, POAI or PYPD? Predictive Oncology has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, PolyPid has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Do analysts prefer POAI or PYPD? PolyPid has a consensus target price of $12.25, suggesting a potential upside of 153.62%. Given PolyPid's stronger consensus rating and higher probable upside, analysts plainly believe PolyPid is more favorable than Predictive Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00PolyPid 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryPolyPid beats Predictive Oncology on 11 of the 15 factors compared between the two stocks.How does Predictive Oncology compare to Sharps Technology?Sharps Technology (NASDAQ:STSS) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership. Which has more volatility & risk, STSS or POAI? Sharps Technology has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Do institutionals & insiders hold more shares of STSS or POAI? 17.2% of Sharps Technology shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 1.2% of Sharps Technology shares are held by insiders. Comparatively, 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer STSS or POAI? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sharps Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is STSS or POAI more profitable? Sharps Technology has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. Sharps Technology's return on equity of -157.91% beat Predictive Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Sharps TechnologyN/A -157.91% -154.40% Predictive Oncology -5,065.23%-732.73%-235.55% Which has higher valuation and earnings, STSS or POAI? Predictive Oncology has higher revenue and earnings than Sharps Technology. Predictive Oncology is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSharps Technology$200K399.92-$282.50M-$831.52N/APredictive Oncology$1.66M10.46-$12.66M-$13.50N/A Does the media favor STSS or POAI? In the previous week, Sharps Technology had 3 more articles in the media than Predictive Oncology. MarketBeat recorded 4 mentions for Sharps Technology and 1 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 0.75 beat Sharps Technology's score of 0.34 indicating that Predictive Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sharps Technology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Predictive Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySharps Technology beats Predictive Oncology on 9 of the 13 factors compared between the two stocks.How does Predictive Oncology compare to Spectral AI?Predictive Oncology (NASDAQ:POAI) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation. Which has more volatility and risk, POAI or MDAI? Predictive Oncology has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Spectral AI has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Is POAI or MDAI more profitable? Spectral AI has a net margin of -85.58% compared to Predictive Oncology's net margin of -5,065.23%. Spectral AI's return on equity of 0.00% beat Predictive Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Predictive Oncology-5,065.23% -732.73% -235.55% Spectral AI -85.58%N/A -72.97% Which has preferable earnings and valuation, POAI or MDAI? Spectral AI has higher revenue and earnings than Predictive Oncology. Spectral AI is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPredictive Oncology$1.66M10.46-$12.66M-$13.50N/ASpectral AI$19.65M4.28-$7.57M-$0.53N/A Do analysts rate POAI or MDAI? Spectral AI has a consensus target price of $3.00, suggesting a potential upside of 13.64%. Given Spectral AI's stronger consensus rating and higher probable upside, analysts clearly believe Spectral AI is more favorable than Predictive Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Spectral AI 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals have more ownership in POAI or MDAI? 9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 67.1% of Spectral AI shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by insiders. Comparatively, 13.7% of Spectral AI shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to POAI or MDAI? In the previous week, Spectral AI had 6 more articles in the media than Predictive Oncology. MarketBeat recorded 7 mentions for Spectral AI and 1 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 0.75 beat Spectral AI's score of 0.39 indicating that Predictive Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Predictive Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spectral AI 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySpectral AI beats Predictive Oncology on 12 of the 16 factors compared between the two stocks. Get Predictive Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for POAI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding POAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart POAI vs. The Competition ExportMetricPredictive OncologyMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.41M$1.46B$6.35B$12.29BDividend YieldN/AN/A2.79%5.33%P/E Ratio-0.3864.0621.0925.34Price / Sales10.466.28528.2179.17Price / CashN/A22.7744.1356.16Price / Book-11.156.3610.007.01Net Income-$12.66M-$54.76M$3.55B$335.27M7 Day Performance-8.39%5.64%1.98%1.28%1 Month Performance5.12%10.59%-0.88%0.16%1 Year Performance-65.10%1.41%36.38%34.54% Predictive Oncology Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)POAIPredictive Oncology0.2116 of 5 stars$5.13+7.8%N/A-68.6%$17.41M$1.66MN/A30Gap DownQTIQT Imaging0.593 of 5 stars$7.59+6.2%N/A+530.0%$86.10M$18.92MN/AN/AHigh Trading VolumeSKINBeauty Health2.7153 of 5 stars$0.65+0.7%$2.32+254.4%-57.7%$83.05M$300.80MN/A1,030Analyst ForecastPYPDPolyPid3.1187 of 5 stars$4.56+5.1%$12.25+168.6%+71.9%$82.82MN/AN/A80Analyst RevisionGap DownHigh Trading VolumeSTSSSharps Technology0.771 of 5 stars$2.00-4.3%N/A-50.4%$80.81M$204.12KN/A3Earnings ReportAnalyst Downgrade Related Companies and Tools Related Companies QT Imaging Competitors Beauty Health Competitors PolyPid Competitors Sharps Technology Competitors Spectral AI Competitors LENSAR Competitors Baird Medical Investment Competitors Outset Medical Competitors Alpha Pro Tech Competitors InspireMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:POAI) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Predictive Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Predictive Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
